Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 283

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis

Open access
Falagas, Matthew E., Tansarli, Giannoula S., Ikawa, Kazuro, Vardakas, Konstantinos Z.·2013·Clinical Infectious Diseases
DOI 10.1093/cid/cis857
Open this paper in CoChat — free account

Abstract

We sought to study whether the better pharmacokinetic and pharmacodynamic (PK/PD) properties of carbapenems and piperacillin/tazobactam, when the duration of infusion is longer, were associated with lower mortality. PubMed and Scopus were searched for studies reporting on patients treated with extended (≥3 hours) or continuous (24 hours) versus short-term duration (20-60 minutes) infusions of carbapenems or piperacillin/tazobactam. Fourteen studies were included (1229 patients). Mortality was lower among patients receiving extended or continuous infusion of carbapenems or piperacillin/tazobactam compared to those receiving short-term (risk ratio [RR], 0.59; 95% confidence interval [CI], .41-.83). Patients with pneumonia who received extended or continuous infusion had lower mortality than those receiving short-term infusion (RR, 0.50; 95% CI, 0.26-0.96). Data for other specific infections were not available. The available evidence from mainly nonrandomized studies suggests that extended or continuous infusion of carbapenems or piperacillin/tazobactam was associated with lower mortality. Well-designed randomized controlled trials are warranted to confirm these findings before such approaches become widely used.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/cis857

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 51

  1. Baughman, 2009, The use of carbapenems in the treatment of serious infections, J Intensive Care Med, 24, 230, 10.1177/0885066609335660 · DOI
  2. Michalopoulos, 2012, Treatment of Acinetobacter infections, Expert Opin Pharmacother, 11, 779, 10.1517/14656561003596350 · DOI · Paper page
  3. Thiem, 2011, Elderly patients with community-acquired pneumonia: optimal treatment strategies, Drugs Aging, 28, 519, 10.2165/11591980-000000000-00000 · doi:10.2165/11591980-000000000-00000
  4. Jaruratanasirikul, 2005, Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection, Antimicrob Agents Chemother, 49, 1337, 10.1128/AAC.49.4.1337-1339.2005 · DOI
  5. Li, 2005, Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection, J Antimicrob Chemother, 56, 388, 10.1093/jac/dki243 · DOI
  6. Lodise, 2004, Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation, Antimicrob Agents Chemother, 48, 4718, 10.1128/AAC.48.12.4718-4724.2004 · DOI
  7. Roberts, 2010, First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis, Int J Antimicrob Agents, 35, 156, 10.1016/j.ijantimicag.2009.10.008 · DOI · Paper page
  8. Thalhammer, 1999, Continuous infusion versus intermittent administration of meropenem in critically ill patients, J Antimicrob Chemother, 43, 523, 10.1093/jac/43.4.523 · DOI
  9. Roberts, 2009, A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics, Crit Care Med, 37, 2071, 10.1097/CCM.0b013e3181a0054d · DOI · Paper page
  10. Tamma, 2011, Does prolonged beta-lactam infusion improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials, BMC Infect Dis, 11, 181, 10.1186/1471-2334-11-181 · DOI
  11. Kasiakou, 2005, Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials, Lancet Infect Dis, 5, 581, 10.1016/S1473-3099(05)70218-8 · DOI · Paper page
  12. Mah, 2012, Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review, Ann Pharmacother, 46, 265, 10.1345/aph.1Q378 · DOI
  13. Buck, 2005, Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion, Int J Antimicrob Agents, 25, 62, 10.1016/j.ijantimicag.2004.08.012 · DOI
  14. Dow, 2011, Retrospective study of prolonged versus intermittent infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center, Infect Dis Clin Pract, 19, 413, 10.1097/IPC.0b013e31822e9bf5 · doi:10.1097/ipc.0b013e31822e9bf5
  15. Grant, 2002, Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital, Pharmacotherapy, 22, 471, 10.1592/phco.22.7.471.33665 · DOI
  16. Itabashi, 2007, Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia, Japan J Antibiot, 60, 161
  17. Lau, 2006, Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection, Antimicrob Agents Chemother, 50, 3556, 10.1128/AAC.00329-06 · DOI
  18. Lodise, 2007, Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy, Clin Infect Dis, 44, 357, 10.1086/510590 · DOI · Paper page
  19. Lorente, 2009, Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion, Int J Antimicrob Agents, 33, 464, 10.1016/j.ijantimicag.2008.10.025 · DOI
  20. Lorente, 2006, Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli, Ann Pharmacother, 40, 219, 10.1345/aph.1G467 · DOI · Paper page
  21. Okimoto, 2009, Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly, Nihon Kokyuki Gakkai Zasshi, 47, 553
  22. Patel, 2009, Outcomes of extended infusion piperacillin/tazobactam for documented gram-negative infections, Diagn Microbiol Infect Dis, 64, 236, 10.1016/j.diagmicrobio.2009.03.002 · doi:10.1016/j.diagmicrobio.2009.03.002
  23. Sakka, 2007, Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial, Antimicrob Agents Chemother, 51, 3304, 10.1128/AAC.01318-06 · DOI · Paper page
  24. Wang, 2009, Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii, Int J Antimicrob Agents, 33, 290, 10.1016/j.ijantimicag.2008.09.012 · DOI
  25. Rafati, 2006, Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients, Int J Antimicrob Agents, 28, 122, 10.1016/j.ijantimicag.2006.02.020 · DOI
  26. Kojika, 2005, A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time, Jpn J Antibiot, 58, 452
  27. Pedeboscq, 2001, Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin, Pathol Biol (Paris), 49, 540
  28. Yost, 2011, The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study, Pharmacotherapy, 31, 767, 10.1592/phco.31.8.767 · DOI
  29. Falagas, 2006, Cure of persistent, post-appendectomy Klebsiella pneumoniae septicaemia with continuous intravenous administration of meropenem, Scand J Infect Dis, 38, 807, 10.1080/00365540500504125 · doi:10.1080/00365540500504125
  30. Taccone, 2012, Optimal meropenem concentrations to treat multi-drug resistant Pseudomonas aeruginosa septic shock, Antimicrob Agents Chemother, 56, 2129, 10.1128/AAC.06389-11 · DOI
  31. Paul, 2010, Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams, Cochrane Database Syst Rev, 11, CD005197
  32. Siempos, 2007, Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia, Eur Respir J, 29, 548, 10.1183/09031936.00080206 · DOI
  33. Vardakas, 2012, Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design, Mayo Clinic Proceedings, 87, 349, 10.1016/j.mayocp.2011.12.011 · DOI
  34. Drusano, 2003, Prevention of resistance: a goal for dose selection for antimicrobial agents, Clin Infect Dis, 36, S42, 10.1086/344653 · DOI · Paper page
  35. Kim, 2009, Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia, Clin Ther, 31, 2765, 10.1016/j.clinthera.2009.11.026 · doi:10.1016/j.clinthera.2009.11.026
  36. Lee, 2010, Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation, Diagn Microbiol Infect Dis, 68, 251, 10.1016/j.diagmicrobio.2010.06.012 · doi:10.1016/j.diagmicrobio.2010.06.012
  37. Roberts, 2009, Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution, J Antimicrob Chemother, 64, 142, 10.1093/jac/dkp139 · DOI · Paper page
  38. Kikuchi, 2009, Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions, Antimicrob Agents Chemother, 53, 2799, 10.1128/AAC.01578-08 · DOI
  39. Krueger, 2005, Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers, Antimicrob Agents Chemother, 49, 1881, 10.1128/AAC.49.5.1881-1889.2005 · DOI
  40. Gin, 2007, Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination, Expert Rev Anti Infect Ther, 5, 365, 10.1586/14787210.5.3.365 · DOI
  41. Nicolau, 2008, Carbapenems: a potent class of antibiotics, Expert Opin Pharmacother, 9, 23, 10.1517/14656566.9.1.23 · DOI · Paper page
  42. Perrott, 2010, Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review, Ann Pharmacother, 44, 557, 10.1345/aph.1M339 · DOI
  43. Peterson, 2005, Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance, Clin Microbiol Infect, 11, 4, 10.1111/j.1469-0691.2005.01238.x · DOI
  44. Zanetti, 2003, Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study, Antimicrob Agents Chemother, 47, 3442, 10.1128/AAC.47.11.3442-3447.2003 · DOI · Paper page
  45. Florea, 2003, Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study, Am J Health Syst Pharm, 60, 2321, 10.1093/ajhp/60.22.2321 · DOI
  46. Safdar, 2004, Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis, Lancet Infect Dis, 4, 519, 10.1016/S1473-3099(04)01108-9 · DOI · Paper page
  47. Bliziotis, 2011, Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia, PLoS One, 6, e26470, 10.1371/journal.pone.0026470 · doi:10.1371/journal.pone.0026470
  48. Furno, 2002, Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis, Lancet Infect Dis, 2, 231, 10.1016/S1473-3099(02)00241-4 · DOI
  49. Paul, 2004, Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials, BMJ, 328, 668, 10.1136/bmj.38028.520995.63 · DOI · Paper page
  50. Paul, 2006, Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials, J Antimicrob Chemother, 57, 176, 10.1093/jac/dki448 · DOI · Paper page
  51. Traugott, 2011, Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum, Pharmacotherapy, 31, 598, 10.1592/phco.31.6.598 · DOI

Cited by

See all 283

Metadata

Authors
Falagas, M. E., Tansarli, G. S., Ikawa, K., & Vardakas, K. Z.
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2012-10-16
Volume
56
Issue
2
Pages
272-282
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
DOI
10.1093/cid/cis857
OpenAlex
W2150263213
Cited by
283
References
2
FWCI
4.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1093/cid/cis857
The paper
Falagas, M. E., Tansarli, G. S., Ikawa, K., & Vardakas, K. Z. (2013). Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cis857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.